NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma - sprookjes - yvandenbroek - TriplyDB

NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma

NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma

http://www.wikidata.org/entity/Q21563424

about

Barrett's oesophagus and oesophageal adenocarcinoma: time for a new synthesis Genetic Biomarkers of Barrett's Esophagus Susceptibility and Progression to Dysplasia and Cancer: A Systematic Review and Meta-Analysis Early events during neoplastic progression in Barrett's esophagus Predictive biomarkers for Barrett's esophagus: so near and yet so far Research Needs for Understanding the Biology of Overdiagnosis in Cancer Screening.The Presence of Genetic Mutations at Key Loci Predicts Progression to Esophageal Adenocarcinoma in Barrett's Esophagus NSAIDs modulate clonal evolution in Barrett's esophagus.Clinical puzzle: Barrett's oesophagus.p16 mutation spectrum in the premalignant condition Barrett's esophagus.Genomics, Endoscopy, and Control of Gastroesophageal Cancers: A Perspective.The role of genetic diversity in cancer.Evidence for DNA damage checkpoint activation in barrett esophagus Translation of an STR-based biomarker into a clinically compatible SNP-based platform for loss of heterozygosity.Application of biomarkers in cancer risk management: evaluation from stochastic clonal evolutionary and dynamic system optimization points of view.The molecular basis of carcinogenesis in Barrett's esophagus.Single nucleotide polymorphism-based genome-wide chromosome copy change, loss of heterozygosity, and aneuploidy in Barrett's esophagus neoplastic progression.Barrett's esophagus and cancer risk: how research advances can impact clinical practice.Biomarkers in Barrett's Esophagus.Comparison of nuclear texture analysis and image cytometric DNA analysis for the assessment of dysplasia in Barrett's oesophagus.The microRNAs, MiR-31 and MiR-375, as candidate markers in Barrett's esophageal carcinogenesis Selenium, selenoenzymes, oxidative stress and risk of neoplastic progression from Barrett's esophagus: results from biomarkers and genetic variants.Passenger mutations as a marker of clonal cell lineages in emerging neoplasia Biomarkers in Barrett's esophagus and esophageal adenocarcinoma: predictors of progression and prognosis.A comprehensive survey of clonal diversity measures in Barrett's esophagus as biomarkers of progression to esophageal adenocarcinoma.Biomarkers of Barrett's esophagus.Inflammation and oxidative stress markers and esophageal adenocarcinoma incidence in a Barrett's esophagus cohort.Deep clonal profiling of formalin fixed paraffin embedded clinical samples Molecular markers and imaging tools to identify malignant potential in Barrett's esophagus Correlation of the presence and extent of loss of heterozygosity mutations with histological classifications of Barrett's esophagus.The role of tobacco, alcohol, and obesity in neoplastic progression to esophageal adenocarcinoma: a prospective study of Barrett's esophagus Next-generation sequencing of endoscopic biopsies identifies ARID1A as a tumor-suppressor gene in Barrett's esophagus Integrative post-genome-wide association analysis of CDKN2A and TP53 SNPs and risk of esophageal adenocarcinoma.Warburg and Crabtree effects in premalignant Barrett's esophagus cell lines with active mitochondria.The combination of autofluorescence endoscopy and molecular biomarkers is a novel diagnostic tool for dysplasia in Barrett's oesophagus.Progressive silencing of p14ARF in oesophageal adenocarcinoma.Deletion at fragile sites is a common and early event in Barrett's esophagus.Prediction of response to endoscopic therapy of Barrett's dysplasia by using genetic biomarkers.New strategies in Barrett's esophagus: integrating clonal evolutionary theory with clinical management Addressing overdiagnosis and overtreatment in cancer: a prescription for change From genomics to diagnostics of esophageal adenocarcinoma.

P2860

Q24602426-262B9D50-3050-4971-BAD2-A6FCC0E84F7B Q26786469-9B660040-4314-46B7-90C8-912859368D2C Q26825349-E0C7AA7D-0FCE-4678-8C07-CB308B1C82A2 Q26849403-CEAB6D31-9E32-422B-87B9-1DF94052A8DC Q30252065-357F69E2-8BB4-4FD8-86E8-07EE350993C7 Q30654762-71C13056-F1BA-45DE-AC8F-2CFE44BCEE02 Q31119674-E217CCBA-2A28-4BF2-9212-A8F984D6324D Q33346381-840F6E84-91B8-4940-B494-785A37D951B1 Q33388259-F79A9E2C-1715-4787-9A89-A3BAD86BB860 Q33600507-B0B34F9C-4742-481A-8860-E0E09AE8F632 Q33604953-7790482B-BE7C-408D-9315-36E93502F4D0 Q33655360-9B97712F-CFF4-4FD8-9565-C83D240A509C Q33817740-EB751366-6DE5-430D-A9A5-E52253E993BC Q33842160-784C1CFB-8DA3-4FC5-9867-9A3727823784 Q33862429-6B2F0154-4820-4660-818C-E0B9537B4AFD Q33902184-A4AD3917-9A78-4AF5-9355-9F93C70BBAF8 Q33959620-5BFDAD58-490E-4C20-8A72-343A3087614A Q34011000-1F27DFB7-8AF5-4BDB-A264-F1701975C77D Q34024948-A444AE07-8AC0-4DDF-BAAE-4DDF9A00343D Q34149750-4212F538-B566-4E15-8DCC-24F7BE28B30E Q34310309-49C2C9CF-7EB5-432D-820B-008D5F2A0155 Q34361056-FEDC6AF6-D7E8-424A-A1A0-A4997CEC856B Q34385125-ACE0D8CB-6D56-4C9E-A2A1-3CFDC39C183A Q34418880-C44B9957-8144-4E06-878C-8BDD7D96878D Q34448115-A2D048D4-4ECA-419E-9A66-93D3436567EF Q34457732-9AFBD8B6-5AAF-4752-8D1C-784F23D1F907 Q34505542-FF95706E-8C55-4C5B-9C16-04DDFD67A577 Q34508850-8D954B9F-FFF2-432B-BC98-A5F9FF603AFD Q34523644-ACAAFD58-7D97-4FD8-9430-6F7978EB12B3 Q34542075-8BB42210-C1A4-4229-B36E-259BD2D31755 Q34547790-4816EB3B-9DFD-47A0-8A43-169FBD153B8A Q34586242-7E516F5F-9395-47FF-A828-91E606D20DC6 Q34608393-5F0750C9-5F1F-4CF9-BC6B-DBDB1DE857F0 Q34818554-A3DF0AC8-2607-4E77-AF12-25638125AAA5 Q34995366-E8AAF1B4-C8A8-4109-81B9-BBABA61975EF Q35002032-DAF7EDC7-7541-42C6-8918-8083968F7C52 Q35031044-D6A11470-2599-4A0C-83D5-AA857A586D23 Q35057339-A36E0202-284A-4BA6-81A4-562CD95CEDB2 Q35067706-6D50EC2A-58D5-4A1F-94D0-5035B46CF2FA Q35073507-2DAFC4C9-D9B7-4046-8705-605D1A98EDA4

P2860

NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma

http://www.wikidata.org/entity/Q21563424

description

2007 nî lūn-bûn

@nan

2007 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

NSAIDs modulate CDKN2A, TP53, ...... n to esophageal adenocarcinoma

@ast

NSAIDs modulate CDKN2A, TP53, ...... n to esophageal adenocarcinoma

@en

NSAIDs modulate CDKN2A, TP53, ...... n to esophageal adenocarcinoma

@en-gb

NSAIDs modulate CDKN2A, TP53, ...... n to esophageal adenocarcinoma

@nl

type

label

NSAIDs modulate CDKN2A, TP53, ...... n to esophageal adenocarcinoma

@ast

NSAIDs modulate CDKN2A, TP53, ...... n to esophageal adenocarcinoma

@en

NSAIDs modulate CDKN2A, TP53, ...... n to esophageal adenocarcinoma

@en-gb

NSAIDs modulate CDKN2A, TP53, ...... n to esophageal adenocarcinoma

@nl

altLabel

NSAIDs Modulate CDKN2A, TP53, ...... n to Esophageal Adenocarcinoma

@en

prefLabel

NSAIDs modulate CDKN2A, TP53, ...... n to esophageal adenocarcinoma

@ast

NSAIDs modulate CDKN2A, TP53, ...... n to esophageal adenocarcinoma

@en

NSAIDs modulate CDKN2A, TP53, ...... n to esophageal adenocarcinoma

@en-gb

NSAIDs modulate CDKN2A, TP53, ...... n to esophageal adenocarcinoma

@nl

P1433

Q21563424-1B9F3FBB-3AF5-40CC-99E3-0332D1DA5A5D

P1476

Q21563424-3B642348-D14F-4436-ABB9-C83D1C6DF32B

P2093

Q21563424-0C47E048-444B-4234-97F1-D7734D56BFEA

Q21563424-17D0FF30-C5A5-4D9D-A3F9-B02757B49616

Q21563424-41789FAA-F4DC-4C0F-A851-35343A386516

Q21563424-72849F01-1DBD-4637-A12A-8413A9600415

Q21563424-7E1927BB-2EDE-424B-BA4F-3FCF74DB9BEF

Q21563424-95CCFED3-0385-4CCF-A5C3-0925A015ED99

Q21563424-BE76A682-8105-4AA5-AAEF-6ABF85C1F9FD

Q21563424-EF69D634-577F-468A-B229-BBF9D7FD212B

P2860

Q21563424-01BF8576-85A9-43AA-809A-F67155723757

Q21563424-02A3DBF5-217B-4E60-A3AC-D4350AF09A5B

Q21563424-082433F3-B0E9-4D77-8F0A-0B2A034C476C

Q21563424-092DF047-AC51-4A80-85D7-0E1414194DEC

Q21563424-0A003269-EB38-4BD5-A1A7-A4B45C3B66F2

Q21563424-0AF163E9-2628-4019-B25C-074CA60561CE

Q21563424-0C4F62CB-7E45-4E60-8899-07DB0643219A

Q21563424-1003F512-C85F-4BBD-BF4A-5C96FA602DE1

Q21563424-1141D408-80DF-4370-8BCB-EF7DB4EA5714

Q21563424-16BC57C5-0138-4E4B-B91B-7A6C878F7FAF

P304

Q21563424-691C5911-6589-4490-8D50-784A04E48F52

P31

Q21563424-A004EF45-9759-41E6-AA7B-4B5065599549

P3181

Q21563424-2C281440-B21A-4AB2-A7E7-7D1590B6DF30

P356

Q21563424-45C8DF92-94CA-43BE-AA58-8005652617D3

P407

Q21563424-44735A9F-CDD4-4D6B-91C4-89DFB4A38BBE

P433

Q21563424-D8A13B24-9188-4513-9A09-D429A69E7A79

P478

Q21563424-D659A7B9-E4C3-49BB-8A33-91DC3847F0A6

P50

Q21563424-0F4A0993-4054-48DA-A79D-72D7D1BD310F

Q21563424-855DD6F8-3443-4D01-82BD-2AFB30985693

P577

Q21563424-D2EEE446-218F-40D5-9E38-74BD0CBC402E

P5875

Q21563424-6C4B3E25-ED57-42FF-A794-0DAABC38DE0B

P698

Q21563424-7ACA69CE-3F4D-4AC5-940E-3733F8BF5322

P921

Q21563424-AFEC23EA-2387-4E11-9F18-60D39789468C

P932

Q21563424-FEE6DC6C-F2CF-4465-9DBC-F766E4C5D297

P3181

P356

JOURNAL.PMED.0040067

P1433

P1476

NSAIDs modulate CDKN2A, TP53, ...... n to esophageal adenocarcinoma

@en

P2093

Brian J Reid

http://www.w3.org/2001/XMLSchema#string

Carissa A Sanchez

http://www.w3.org/2001/XMLSchema#string

Carlo C Maley

http://www.w3.org/2001/XMLSchema#string

Kamran Ayub

http://www.w3.org/2001/XMLSchema#string

Patricia C Galipeau

http://www.w3.org/2001/XMLSchema#string

Robert D Odze

http://www.w3.org/2001/XMLSchema#string

Thomas L Vaughan

http://www.w3.org/2001/XMLSchema#string

Xiaohong Li

http://www.w3.org/2001/XMLSchema#string

P2860

p53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17p13.3

Aspirin use and cancers of the upper aerodigestive tract

Evolution of neoplastic cell lineages in Barrett oesophagus

Effects of non-steroidal anti-inflammatory drugs on cancer sites other than the colon and rectum: a meta-analysis

A genetic model for colorectal tumorigenesis

Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial

Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues

NSAID inhibition of GI cancer growth: clinical implications and molecular mechanisms of action

Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis

A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer

P304

e67

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2274904

http://www.w3.org/2001/XMLSchema#string

P356

10.1371/JOURNAL.PMED.0040067

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P50

P S Rabinovitch

Patricia L Blount

P577

2007-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6479284

http://www.w3.org/2001/XMLSchema#string

P698

17326708

http://www.w3.org/2001/XMLSchema#string

P921

P932

1808095

http://www.w3.org/2001/XMLSchema#string